TScan Therapeutics (TCRX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
TCRX slides 3.3% to $0.23. Closed at $0.23, -3.35% vs the prior close of $0.24. Day range $0.23–$0.25, opened at $0.24.
TCRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — TCRX slides 3.3% to $0.23
- Closed at $0.23, -3.35% vs the prior close of $0.24. Day range $0.23–$0.25, opened at $0.24.
- Volume was 568.22K shares, 0.7x its 50-day average of 816.88K.
- Price is -51.3% vs its 50-day average ($0.47) and -74.3% vs its 200-day average ($0.90).
- 52-week range $0.20–$2.57; today's close sits at 1% of that range, 91.0% below the 52-week high.
Oct 15, 2026 — TCRX jumps 13.3% to $0.24
- Closed at $0.24, +13.27% vs the prior close of $0.21. Day range $0.21–$0.24, opened at $0.22.
- Volume was 878.80K shares, 1.1x its 50-day average of 805.27K.
- Price is -50.7% vs its 50-day average ($0.48) and -73.5% vs its 200-day average ($0.90).
- 52-week range $0.20–$2.57; today's close sits at 2% of that range, 90.7% below the 52-week high.
Oct 14, 2026 — TCRX dips 2.8% to $0.21, a 52-week low, 3 down days in a row
- Closed at $0.21, -2.76% vs the prior close of $0.22. Day range $0.20–$0.23, opened at $0.22.
- Volume was 546.60K shares, 0.7x its 50-day average of 810.26K.
- Price is -57.4% vs its 50-day average ($0.50) and -76.7% vs its 200-day average ($0.91).
- 52-week range $0.20–$2.57; today's close sits at 0% of that range, 91.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — TCRX slides 8.8% to $0.22, a 52-week low
- Closed at $0.22, -8.82% vs the prior close of $0.24. Day range $0.21–$0.24, opened at $0.24.
- Volume was 461.40K shares, 0.6x its 50-day average of 809.86K — lighter than usual.
- Price is -57.1% vs its 50-day average ($0.51) and -76.1% vs its 200-day average ($0.91).
- 52-week range $0.21–$2.57; today's close sits at 0% of that range, 91.6% below the 52-week high.
Oct 12, 2026 — TCRX ends flat (+0.0%) to $0.24
- Closed at $0.24, +0.00% vs the prior close of $0.24. Day range $0.23–$0.25, opened at $0.24.
- Volume was 483.50K shares, 0.6x its 50-day average of 805.27K.
- Price is -53.9% vs its 50-day average ($0.52) and -74.0% vs its 200-day average ($0.91).
- 52-week range $0.22–$2.57; today's close sits at 1% of that range, 90.7% below the 52-week high.
Oct 9, 2026 — TCRX jumps 4.4% to $0.24
- Closed at $0.24, +4.39% vs the prior close of $0.23. Day range $0.23–$0.25, opened at $0.23.
- Volume was 869.30K shares, 1.1x its 50-day average of 796.49K.
- Price is -54.8% vs its 50-day average ($0.53) and -74.1% vs its 200-day average ($0.92).
- 52-week range $0.22–$2.57; today's close sits at 1% of that range, 90.7% below the 52-week high.
Oct 8, 2026 — TCRX slides 17.7% to $0.23, a 52-week low on 2.0x normal volume
- Closed at $0.23, -17.69% vs the prior close of $0.28. Day range $0.22–$0.27, opened at $0.27.
- Volume was 1.53M shares, 2.0x its 50-day average of 777.99K — unusually heavy trading.
- Price is -57.5% vs its 50-day average ($0.54) and -75.2% vs its 200-day average ($0.92).
- 52-week range $0.22–$2.57; today's close sits at 0% of that range, 91.1% below the 52-week high.
Oct 7, 2026 — TCRX rises 0.7% to $0.28
- Closed at $0.28, +0.73% vs the prior close of $0.28. Day range $0.26–$0.28, opened at $0.27.
- Volume was 542.10K shares, 0.7x its 50-day average of 781.49K.
- Price is -49.4% vs its 50-day average ($0.55) and -70.0% vs its 200-day average ($0.92).
- 52-week range $0.26–$2.57; today's close sits at 1% of that range, 89.2% below the 52-week high.
Oct 6, 2026 — TCRX slides 6.8% to $0.28, a 52-week low
- Closed at $0.28, -6.78% vs the prior close of $0.29. Day range $0.26–$0.30, opened at $0.29.
- Volume was 601.90K shares, 0.8x its 50-day average of 787.60K.
- Price is -50.6% vs its 50-day average ($0.56) and -70.3% vs its 200-day average ($0.93).
- 52-week range $0.26–$2.57; today's close sits at 0% of that range, 89.3% below the 52-week high.
Oct 5, 2026 — TCRX slides 8.1% to $0.29, a 52-week low
- Closed at $0.29, -8.10% vs the prior close of $0.32. Day range $0.28–$0.33, opened at $0.32.
- Volume was 749.90K shares, 0.9x its 50-day average of 793.86K.
- Price is -48.0% vs its 50-day average ($0.57) and -68.3% vs its 200-day average ($0.93).
- 52-week range $0.28–$2.57; today's close sits at 0% of that range, 88.5% below the 52-week high.
Oct 2, 2026 — TCRX rises 0.9% to $0.32
- Closed at $0.32, +0.94% vs the prior close of $0.32. Day range $0.32–$0.33, opened at $0.33.
- Volume was 144.40K shares, 0.2x its 50-day average of 812.62K — lighter than usual.
- Price is -44.4% vs its 50-day average ($0.58) and -65.6% vs its 200-day average ($0.93).
- 52-week range $0.29–$2.57; today's close sits at 1% of that range, 87.5% below the 52-week high.
TCRX latest news & SEC filings
Every SEC filing by or about TCRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Oct 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Macbeath Gavin received an award of 1,000,000 shares on Oct 1, 2026; now holds 1,049,767
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Zdraveski Zoran received an award of 300,000 shares on Oct 1, 2026; now holds 304,716
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 25, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.05 — Costs tied to exiting activities / restructuring.
- Item 3.01 — Stock exchange listing notice or transfer of listing.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.02 — Ended a material agreement.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.05M (prior year $3.08M) (-65.8% vs Jun 30, 2025)
- Net income: -$30.36M (prior year -$36.95M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.23 (prior year -$0.28) (loss narrowed vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade TCRX
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Mar 4, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.89% (largest 17.7%). That is a volatile stock.
- Liquidity: about 670.56K shares (≈$154.90K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.23 vs a range of $0.20–$2.57 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 24 open-market buys, 0 sales; latest: Capital Management Lp Lynx1 bought 6,232 shares on Dec 23, 2025.
- Latest filings: 8-K Oct 16, 2026; 8-K Sep 30, 2026; 8-K Sep 11, 2026.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
TCRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.24 | 0.25 | 0.23 | 0.23 | 568.22K |
| Oct 15, 2026 | 0.22 | 0.24 | 0.21 | 0.24 | 878.80K |
| Oct 14, 2026 | 0.22 | 0.23 | 0.20 | 0.21 | 546.60K |
| Oct 13, 2026 | 0.24 | 0.24 | 0.21 | 0.22 | 461.40K |
| Oct 12, 2026 | 0.24 | 0.25 | 0.23 | 0.24 | 483.50K |
| Oct 9, 2026 | 0.23 | 0.25 | 0.23 | 0.24 | 869.30K |
| Oct 8, 2026 | 0.27 | 0.27 | 0.22 | 0.23 | 1.53M |
| Oct 7, 2026 | 0.27 | 0.28 | 0.26 | 0.28 | 542.10K |
| Oct 6, 2026 | 0.29 | 0.30 | 0.26 | 0.28 | 601.90K |
| Oct 5, 2026 | 0.32 | 0.33 | 0.28 | 0.29 | 749.90K |
| Oct 2, 2026 | 0.33 | 0.33 | 0.32 | 0.32 | 144.40K |
| Oct 1, 2026 | 0.32 | 0.33 | 0.31 | 0.32 | 622.70K |
| Sep 30, 2026 | 0.32 | 0.34 | 0.31 | 0.31 | 554.40K |
| Sep 29, 2026 | 0.34 | 0.35 | 0.31 | 0.32 | 753.20K |
| Sep 28, 2026 | 0.34 | 0.35 | 0.32 | 0.34 | 359.20K |
| Sep 25, 2026 | 0.35 | 0.37 | 0.33 | 0.34 | 381.90K |
| Sep 24, 2026 | 0.37 | 0.37 | 0.34 | 0.35 | 606.70K |
| Sep 23, 2026 | 0.36 | 0.37 | 0.34 | 0.36 | 1.08M |
| Sep 22, 2026 | 0.33 | 0.36 | 0.33 | 0.35 | 918.50K |
| Sep 21, 2026 | 0.31 | 0.34 | 0.31 | 0.33 | 752.90K |
About TScan Therapeutics
TScan Therapeutics (TCRX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in WALTHAM, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1783328.
TCRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| L.P. 667, | Director | May 22, 2026 |
| Bros. Advisors Lp Baker | Director | May 22, 2026 |
| Felix Baker | Director | May 22, 2026 |
| Julian Baker | Director | May 22, 2026 |
| Bros. Advisors (Gp) Llc Baker | Director | May 22, 2026 |
| Brothers Life Sciences Lp Baker | Director | May 22, 2026 |
| Katina Dorton | Director | May 22, 2026 |
| Gabriela Gruia | Director | May 22, 2026 |
| Barbara Klencke | Director | May 22, 2026 |
| Gavin Macbeath | Chief Executive Officer | Jan 22, 2026 |
| Garry A Nicholson | Director | May 22, 2026 |
| Keith Woods | Director | May 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jason Amello | Chief Financial Officer | Jan 22, 2026 |
| Leiden Dworak | See Remarks | Jan 22, 2026 |
| Chrystal Louis | Chief Medical Officer | Jan 22, 2026 |
| Gavin Macbeath | Chief Executive Officer | Jan 22, 2026 |
| Zoran Zdraveski | See Remarks | Jan 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Dec 23, 2025 | Capital Management Lp Lynx1 | Buy | 6,232 | $0.90 |
| Dec 23, 2025 | Capital Management Lp Lynx1 | Buy | 6,232 | $0.90 |
| Dec 23, 2025 | Weston Nichols | Buy | 6,232 | $0.90 |
| Dec 23, 2025 | Weston Nichols | Buy | 6,232 | $0.90 |
| Dec 23, 2025 | Capital Management Lp Lynx1 | Buy | 6,232 | $0.90 |
| Dec 23, 2025 | Capital Management Lp Lynx1 | Buy | 6,232 | $0.90 |
| Dec 23, 2025 | Weston Nichols | Buy | 6,232 | $0.90 |
| Dec 23, 2025 | Weston Nichols | Buy | 6,232 | $0.90 |
| Dec 22, 2025 | Capital Management Lp Lynx1 | Buy | 75,500 | $0.90 |
| Dec 22, 2025 | Capital Management Lp Lynx1 | Buy | 75,500 | $0.90 |
| Dec 22, 2025 | Weston Nichols | Buy | 75,500 | $0.90 |
| Dec 22, 2025 | Weston Nichols | Buy | 75,500 | $0.90 |
| Dec 22, 2025 | Capital Management Lp Lynx1 | Buy | 75,500 | $0.90 |
| Dec 22, 2025 | Capital Management Lp Lynx1 | Buy | 75,500 | $0.90 |
| Dec 22, 2025 | Weston Nichols | Buy | 75,500 | $0.90 |
TCRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $10.32M | $-129.77M | -1.00 | $-135.32M |
| Dec 31, 2024 | $2.82M | $-127.50M | -1.14 | $-110.82M |
| Dec 31, 2023 | $21.05M | $-89.22M | -1.36 | $-61.36M |
| Dec 31, 2022 | $13.54M | $-66.22M | -2.75 | $-66.50M |
| Dec 31, 2021 | $10.14M | $-48.62M | -4.17 | $-48.68M |
Latest balance sheet: total assets $171.45M, total liabilities $102.43M, cash $100.16M (as of Jun 30, 2026).
TCRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $0.77 |
| May 6, 2026 | 8-K Item 2.02 (results) | $1.25 |
| Mar 4, 2026 | 8-K Item 2.02 (results) | $1.08 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $1.19 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $1.67 |
| May 6, 2025 | 8-K Item 2.02 (results) | $1.36 |
| Mar 5, 2025 | 8-K Item 2.02 (results) | $1.92 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $5.42 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
| Apr 17, 2024 | 8-K Item 2.02 (results) | — |
| Mar 6, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on TCRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.